贝达药业：注射用曲妥珠单抗启动销售

Core Viewpoint - The company has entered into a strategic partnership with Hangzhou Bozhi Rui Biopharmaceutical Co., Ltd. to acquire the rights to the project of Pertuzumab injection and has been granted the distribution rights of Trastuzumab injection (brand name: Anruize) in China [1] Summary by Relevant Sections - Strategic Partnership The company has established a strategic cooperation with Hangzhou Bozhi Rui Biopharmaceutical Co., Ltd. to obtain the project rights for Pertuzumab injection [1] - Product Rights and Distribution The company has been granted the distribution rights for Trastuzumab injection (Anruize) in China, which officially commenced nationwide sales in July 2025 [1] - Regulatory Progress The application for the marketing authorization of Pertuzumab injection was accepted by the National Medical Products Administration in October 2024, and the review and approval process is currently underway [1] - Financial Commitment The company has made the first payment to Bozhi Rui Biopharmaceutical for the project rights of Pertuzumab injection [1]